The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

BACKGROUND: Most patients with acute myeloid leukaemia are older, with many unsuitable for conventional chemotherapy. Low dose Ara-C (LDAC) is superior to best supportive care but is still inadequate. The combination of arsenic trioxide (ATO) and LDAC showed promise in an un-randomised study. We rep...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Burnett, Alan K, Hills, Robert K, Hunter, Ann, Milligan, Donald, Kell, Jonathan, Wheatley, Keith, Yin, John, McMullin, Mary-Frances, Cahalin, Paul, Craig, Jenny, Bowen, David, Russell, Nigel
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6485444/
https://ncbi.nlm.nih.gov/pubmed/21475252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.59
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados